Related Experiment Video
Updated: Aug 29, 2026

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
Antony W Oliver1, Jean-Christophe Amé, S Mark Roe
1Cancer Research UK DNA Repair Enzyme Group, Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK.
Abstract:
Poly(ADP-ribose) polymerase-1 (PARP-1) has become an important pharmacological target in the treatment of cancer due to its cellular role as a 'DNA-strand break sensor', which leads in part to resistance to some existing chemo- and radiological treatments. Inhibitors have now been developed which prevent PARP-1 from synthesizing poly(ADP-ribose) in response to DNA-breaks and potentiate the cytotoxicity of DNA damaging agents. However, with the recent discoveries of PARP-2, which has a similar DNA-damage dependent catalytic activity, and additional members containing the 'PARP catalytic' signature, the isoform selectivity and resultant pharmacological effects of existing inhibitors are brought into question. We present here the crystal structure of the catalytic fragment of murine PARP-2, at 2.8 A resolution, and compare this to the catalytic fragment of PARP-1, with an emphasis on providing a possible framework for rational drug design in order to develop future isoform-specific inhibitors.
Insights
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors are crucial cancer treatments. New research on PARP-2 structure aims to guide the development of more selective and effective PARP inhibitors for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Poly(ADP-ribose) polymerase-1 (PARP-1) is a key target in cancer therapy due to its role in DNA repair.
- PARP-1 inhibitors enhance the efficacy of DNA-damaging cancer treatments.
- The discovery of PARP-2 and other related enzymes raises questions about the isoform selectivity of current PARP inhibitors.
Purpose of the Study:
- To present the crystal structure of the catalytic fragment of murine PARP-2.
- To compare the structure of PARP-2 with PARP-1.
- To provide a basis for the rational design of isoform-specific PARP inhibitors.
Main Methods:
- X-ray crystallography to determine the structure of murine PARP-2 catalytic fragment.
- Structural comparison between PARP-1 and PARP-2 catalytic fragments.
Main Results:
- The crystal structure of the catalytic fragment of murine PARP-2 was determined at 2.8 Å resolution.
- Key structural differences and similarities between PARP-1 and PARP-2 catalytic fragments were identified.
Conclusions:
- The structural insights into PARP-2 can inform the development of novel, isoform-specific PARP inhibitors.
- This research facilitates the design of more targeted cancer therapies with potentially fewer side effects.
- Understanding PARP isoform structures is crucial for advancing cancer pharmacotherapy.
More Related Videos
Related Concept Videos
Eukaryotic RNA Polymerases
All three eukaryotic RNAPs require specific transcription factors, of which the...
RNA Polymerase II Accessory Proteins
RNA Polymerase II Accessory Proteins
ATP Synthase: Structure
Nucleic Acid Structure
DNA Structure
DNA has a double-helix structure. The...
RNA Structure
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA) involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three...

